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ABSTRACT
Multiple sclerosis (MS) is a chronic inflammatory disease of the white matter of the central nervous system
(CNS) characterized by focal areas of demyelination. Interferon- (IFN-) provides an effective treatment
that lessens the frequency and severity of exacerbations in relapsing-remitting multiple sclerosis (RRMS), 
but the mechanisms by which IFN- is efficient remain uncertain. The data presented here demonstrate that
IFN- impairs the proliferative response to myelin basic protein (MBP) and myelin, as well as increasing the
expression of the CTLA4 intracellular molecule. Moreover, this treatment increases the expression of surface
Fas molecules and of the soluble form of these molecules. Our hypothesis is that the increase in Fas and CTLA4
molecules in MS patients may lead to lymphocyte apoptosis, which suggests possible mechanisms underlying
the therapeutic response to IFN-.
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INTRODUCTION
TREATMENT OF RELAPSING-REMITTING multiple sclerosis(RRMS) with interferon- (IFN-) reduces the frequency
and severity of clinical exacerbations and has a beneficial ef-
fect on the progression of the disease.1 The pathogenesis of MS
assumes that autoreactive T lymphocytes and macrophages, af-
ter crossing the blood-brain barrier (BBB), produce central ner-
vous system (CNS) demyelination.2 Therefore, regulation
though the induction of anergy or the elimination of autoreac-
tive T cells may be a possibility for preventing MS lesions.
Two signals are needed for T cell activation. Binding of the
T cell receptor (TCR) to a peptide-MHC complex provides the
first, and the second is provided by cytokines, such as inter-
leukin-2 (IL-2), and costimulatory proteins, such as CD80 and
CD86, expressed on antigen-presenting cells (APCs) or CD28
and CTLA4 molecules expressed on lymphocytes. These CD28
and CTLA4 proteins share amino acid sequences but appear to
serve different functions: crosslinking with the CD28 receptor
enhances T cell activation, whereas that with the CTLA4 re-
ceptor inhibits it.3,4 One previously suggested possibility is that
signaling through CTLA4 may induce apoptosis in activated
cells. It has been suggested that CTLA4 may downregulate the
proliferative response of lymphocytes when the cell surface of
the CTLA4 peaks, correlating with a decrease in survival fac-
tors involved in the mechanisms of apoptosis.5,6
Apoptosis is a physiologic process that plays a critical role
in the elimination of autoreactive T cells and, thus, immune
regulation. Apoptosis of the cells that express the Fas 
molecules (also known as CD95 or APO-1) results from 
the crosslinking of the Fas molecule with the Fas ligand
(FasL).7,8 Mice strains carrying mutations in the Fas (lpr) and
FasL (gld) genes exhibit abnormal lymphocyte proliferation
and autoimmune syndromes.9,10 Cell death in MS, as well as
in its animal model, experimental autoimmune en-
cephalomyelitis (EAE), has been demonstrated to be an es-
sential mechanism in the regulation of the inflammatory re-
action, and infiltrating autoreactive lymphocytes seem to be
eliminated in situ through the apoptotic process.11–15 The in-
volvement of the Fas system in MS and in other neurologic
disorders has been reported, and it may play a role in mod-
ulation of apoptosis.16
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In the present study, the association between the activation
of myelin-specific T lymphocytes in MS patients treated or not
with IFN- was investigated, as was the expression of CTLA4
and Fas molecules in these individuals.
MATERIALS AND METHODS
Patients
The patients in this study were identified using the criteria of
Poser et al.17 to define MS. A total of 47 patients with stable
RRMS, secondary progressive MS, and primary progressive MS,
55 patients with RRMS in treatment with IFN-1b, and 30 nor-
mal subjects were studied (Table 1). The control group was re-
cruited from the local community and had no family history of
neurologic or psychiatric illness. Patients were chosen, and Ex-
panded Disability Status Scale (EDSS) scores were assessed in
sequential visits. None of the patients in any of the groups had
received corticosteroids or other immunosuppressive drugs dur-
ing a period of at least 6 months prior to donating blood for the
study. The patients in the treated group had been receiving IFN-
 treatment in standard doses for 18–24 months. This study was
approved by the Ethics Committee of the Universidade Estadual
de Campinas—UNICAMP, and the volunteers gave written in-
formed consent for participation in the study.
Human myelin basic protein
Human myelin basic protein (MBP) was obtained according
to Deibler et al.18
Isolation of human myelin
Humans brains were removed from patients who had died
from nonneurologic causes, with removal occurring an average
of 2 h after death. The white matter was removed, and myelin
was isolated by overlaying the homogenate in isotonic (0.32 M)
sucrose on a denser sucrose (0.85 M) gradient, allowing the
myelin to migrate down to the interface.19,20 The myelin was
then isolated by centrifugation, dialyzed against water at 4°C,
and lyophilized.
Purification of mononuclear cells
Blood samples (15 mL) were collected under sterile condi-
tions. The cells were separated on a Ficoll-Hypaque gradient
(1.077 density), and the cell concentration was adjusted to 2 
106 cells/mL.
Proliferation assay
Peripheral mononuclear blood cells (PBMCs) were purified
using a Ficoll-Hypaque gradient. The cells were suspended in
Hank’s balanced salt solution (HBSS) and washed before the
addition of RPMI 1640 medium supplemented with 5  105M
2-mercaptoethanol, 2 mM L-glutamine, 1 mM sodium pyruvate,
penicillin-streptomycin, 12.5 mM HEPES buffer, pH 7.4, 0.2%
NaHCO3, and 10% AB human serum. The cells were cultured
in 96-well flat-bottom culture plates, 105 per well, in the pres-
ence of 25 g/mL MBP or 10 g/mL human myelin as well as
phytohemagglutinin (PHA) (5 g/mL). Cells were incubated
for 72 h for the nonspecific mitogen and for 144 h for the anti-
gen in a humidified, 5% CO2 atmosphere at 37°C; the plates
were pulsed with 1.0 Ci of 3H-thymidine per well and har-
vested 18 h later. The incorporation of 3H-thymidine was as-
sessed by standard liquid scintillation techniques. The results
were expressed as stimulation index (SI), which is the mean
count per minute (cpm) of stimulated cells/cpm of unstimulated
cells.
Quantification of surface Fas and CTLA4 molecules
Five microliters of biotin anti-Fas antibody or anti-CTLA4
molecules, as well as the isotype controls (PharMingen, San
Diego, CA) were added to the cells (5  106 cells/mL). After
30 min of incubation on ice and two washes with HBSS, avidin-
FITC antibody (5 g/mL) was added. After 30 more min of in-
cubation and further washing, the presence of the Fas or CTLA4
molecules was determined by flow cytometry.
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TABLE 1. SUMMARY OF CLINICAL CHARACTERISTICS OF MS PATIENTS
Parameter IFN--treated MSa Untreated MSb Healthy controls
n 55 47 30
Female/male 37/16 29/18 19/11
Age, years 30 46 29
Mean  SD 9.6 11.2 4.0
Range 16–46 18–57 18–52
Duration of disease, years 10 17
Mean  SD 5.8 6.9
Range 3–24 11–24
EDSSc 4.3  2.0 5.9  1.8
Mean  SD
Range 1.0–8.0 4.0–8.0
aThe treated MS group comprises relapsing-remitting multiple sclerosis.
bThe untreated group comprises stable relapsing-remitting multiple sclerosis; secondary progressive
multiple sclerosis; primary progressive multiple sclerosis.
cEDSS, Expanded Disability Status Scale.
Quantification of surface Fas molecules on CD4 and
CD8 cells
Anti-Fas antibodies (10 L) conjugated with FITC
(PharMingen) and 5 L anti-CD4 or anti-CD8 antibodies (or
both) conjugated with phycoerythrin (PE) (PharMingen) were
added to the cells (2  106 cell/mL). After 30 min of incuba-
tion and appropriate washes, the percentage of Fas molecules
was determined using a Becton Dickinson FACScan (Becton
Dickinson, Mountain View, CA).
Cytometric analysis of intracellular CTLA molecules
Lymphocytes (106 cells/mL) were stimulated with 5.0
g/mL PHA for 20 h, the last 4 h in the presence of 10 g/mL
monensin. After stimulation, cells were washed twice with
HBSS (pH 7.2), fixed 15 min with formaldehyde (2% in phos-
phate-buffered saline [PBS], pH 7.2), permeabilized with PBS
(pH 7.2) containing 0.5% bovine serum albumin (BSA) and
0.5% saponin, and then incubated for 15 min at ambient tem-
perature with the specific monoclonal antibody (mAb) to the
CTLA4 molecule. Cells were then washed and analyzed on a
Becton Dickinson FACScan.
Quantification of soluble Fas molecules
To measure the levels of soluble Fas molecules (sFas) in
sera, an ELISA kit with specific mAbs was used (Opteia-Hu-
man Fas kit, PharMingen). Briefly, an mAb specific for hu-
man Fas was coated on a 96-well plate. Standards and sam-
ples were added to the wells so that any sFas present would
bind to the immobilized antibody. The wells were washed,
and a mixture of biotinylated antihuman Fas antibody with
horseradish peroxidase (HRP)-conjugated streptavidin was
added, producing an antibody-antigen sandwich. The wells
were again washed, and a substrate solution that produces a
blue color with intensity in direct proportion to the amount
of sFas present in the initial sample was added. A stop solu-
tion was used to change the color from blue to yellow, and
the wells were read at 450 nm. All samples were assayed in
duplicate, and the differences between replicate wells were
uniformly 5%.
Statistical analysis
The statistical significance of the results was determined by
a Wilcoxon test, a Kruskal Wallis test, and a Spearman Rank




The proliferative response to PHA was evaluated for the
three groups (untreated MS, treated MS, and healthy donors),
and the results, expressed as SI, are shown in Figure 1A. The
healthy donor group demonstrated an extensive proliferative re-
sponse to PHA (SI  96  48, n  20), which was not signif-
icantly different (p  0.05) from that of the untreated patients
CHANGES IN IMMUNE RESPONSE IN RRMS TREATED WITH IFN- 867
FIG. 1. Proliferative response of lymphocytes from patients
with multiple sclerosis, both with and without treatment with
IFN-, as well as healthy individuals, after stimulation with (A)
PHA, (B) myelin, and (C) MBP. Treatment with IFN- signif-
icantly reduced (*p  0.003) the proliferative response of lym-
phocytes to neuroantigens (myelin and MBP). Results are ex-




(SI  91  85, n  36) or of the treated MS patients (SI 
84.4  89, n  27).
The lymphocyte proliferative response to myelin was eval-
uated for the three groups. The results shown in Figure 1B dem-
onstrate that the lymphocyte blastogenic response increased sig-
nificantly (p  0.003) for the untreated MS patients (SI 
8.2  1.1, n  30) in relation to that of the healthy individuals
(SI  1.3  0.4, n  20). There was no significant difference
(p  0.05) between the treated patients (SI  1.5  1.0, n 
39) and the healthy individuals (SI  1.3  0.4, n  20).
The lymphocyte proliferative response to MBP was also
evaluated. The results in Figure 1C show a significantly higher
response (p  0.003) level for the untreated MS patients (SI 
6.6  4.1, n  28) than for the healthy group (SI  1.6  0.9,
n  20). There was no significant difference (p  0.05) be-
tween the treated patient group (SI  4.3  1.2, n  44) and
the healthy group (SI  1.6  0.9, n  20).
Quantification of CTLA4 molecules
The presence of CTLA4 molecules was quantified by flow
cytometry on the lymphocyte surface and intracellularly in the
two groups of MS patients, both untreated and those treated
with IFN-, as well as in the healthy donor controls. When an-
alyzed on the surface of ex vivo lymphocytes or even after 24
h in culture, no significant changes were observed in the ex-
pression of CTLA4 molecules for the three groups (1.7  0.8%,
1.5  0.2%, 1.4  0.6% for treated patients, untreated patients,
and healthy controls, respectively). Marked changes were ob-
served, however, in the intracellular CTLA4 molecules. The
mean expression of CTLA4 intracellular molecules was 15.8 
2.1% for treated MS patients (n  19) vs. 3.4  0.7% for
healthy controls (n  15), revealing a significant difference be-
tween the two groups (p  0.0001). This expression for the un-
treated patients was statistically equivalent to that for the
healthy subjects (6.2  1.6% and 3.4  0.7%, respectively, n 
9) (p  0.05) (Fig. 2).
Association between lymphocyte proliferative response
to myelin antigens (myelin and MBP) and expression
of intracellular CTLA4 molecules
As CTLA4 molecules are known to inhibit the activation of
T lymphocytes, the increase in these molecules was associated
with the lymphocyte proliferative response to myelin antigens.
The results showed that there is a negative correlation between
intracellular CTLA4 molecules and the lymphocyte prolifera-
tive response to myelin (R2  0.57775, p  0.00757) and to
MBP (R2  0.5215, p  0.0230) for IFN--treated patients.
No correlations were found for untreated patients and healthy
controls. The lymphocyte proliferative response was presented
as delta cpm, which is the mean cpm of stimulated cells minus
the cpm of unstimulated cells (Fig. 3).
Quantification of surface Fas molecule
The surface expression of Fas molecule was studied in 8 MS
patients, both before IFN- therapy and for 6 months after its
initiation. A significantly greater expression (p  0.001) of Fas
surface molecules was observed after treatment (an increase
from 8.5  1.6% to 26.8  1.5%) (Fig. 4).
Quantification of surface Fas on CD4 and 
CD8 cells
Because CD4 T lymphocytes seem to be involved in the
genesis of MS lesions, the expression of surface Fas mole-
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FIG. 2. Percentage of surface (0 h) and intracellular CTLA4 molecules (20 h in culture) in patients with multiple sclerosis,
both with and without treatment with IFN-, as well as healthy individuals. Treatment with IFN- significantly increased (*p 
0.001; **p  0.0001) the intracellular expression of CTLA4 molecules in lymphocytes stimulated with PHA for 20 h in culture.
CTLA4 molecules were quantified by flow cytometry.
cule was determined by two-color flow cytometry. The re-
sults showed an increase (p  0.001) in the percentage of
CD4Fas in the group of treated patients (24.3  1.2%,
n  27) in comparison with the other two groups: 19.2 
0.7% and 22.2  0.8% for healthy individuals (n  17) and
those with untreated MS (n  16), respectively (Fig. 5A).
There was no significant difference in the percentage of
CD8Fas, with 11.7  1.0%, 12.6  1.2%, and 13.6  2%
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FIG. 3. Correlation between intracellular CTLA4 molecule expression and lymphocyte proliferative response to MBP and
myelin. (A) R2  0.35091 (p  0.1317). (B) R2  0.57775 (p  0.00757). (C) R2  0.11765 (p  0.3815). (D) R2 
0.24997 (p  0.2166). (E) R2  0.5215 (p  0.0230). (F) R2  0.21622 (p  0.3207).
for healthy individuals (n  16), and those with treated (n 
26) and untreated MS (n  15) (Fig. 5B).
Quantification of sFas in sera
The administration of IFN- caused the presence of signif-
icantly more sFas molecules in both treated MS patients
(227.8  18.4 pg/mL, n  38) (p  0.003) and untreated ones
(180.1  14.0 pg/mL, n  37) (p  0.004) in comparison with
healthy donors (114.4  10.3 pg/mL, n  20) (Fig. 6).
DISCUSSION
In the present study, the T cell response to myelin antigens
and a nonspecific mitogen was investigated, as well as the ex-
pression of CTLA4 and Fas molecules in the peripheral blood
cells of patients with MS, whether or not being treated with
IFN-.
We have shown that untreated patients evidence a greater
lymphocyte proliferative response to myelin and MPB than do
the normal healthy controls. These results match the findings
of others, which have demonstrated the presence of activated
T cells specifically recognizing the myelin antigen in the pe-
ripheral blood cells in MS patients, although the antigenic tar-
get was confined to the CNS.21,22 These data suggest that the
immune mechanism that maintains the autoreactive lympho-
cytes under control is impaired in MS patients. We were able
to show that the proliferative response to myelin antigens was
significantly reduced in the group of MS patients treated with
IFN-. These results are in agreement with those previously de-
scribed23,24 Thus, such approaches as immunotherapy with
IFN-, which downregulates the activation of T cells, are use-
ful in minimizing the damage of autoreactions.
The mechanisms by which IFN- limits the expansion of
myelin-reactive T cells, however, deserve additional studies.
One possibility that has been suggested is that IFN- acts
mainly by reducing the antigen-presenting capacity of APCs,
which in turn inhibits the effectors functions of autoreactive T
cells25 or by inducing tolerogenic dendritic cells (DCs) in MS
patients.26 Another possibility is the induction of apoptosis in
the T cells27 or modification of the expression of costimulatory
molecules, such as CTLA4.
The importance of the CTLA4 molecule in demyelination
has been demonstrated in the experimental model of EAE for
studying MS. Blocking of CTLA4 accelerates the onset of EAE
and is associated with an increased frequency of inflammatory
lesions in the CNS, enhanced secretion of proinflammatory cy-
tokines, and increased proliferative responses to in vitro anti-
gen stimulation.28,29 In the present study, the number of intra-
cellular CTLA4 molecules increased in MS patients treated with
IFN-. This increase correlated with a decrease in the prolifer-
ative response of the T cells to myelin antigens. The intracel-
lular portion of the CTLA4 tends to be highly conserved for
various species, which suggests that control of intracellular traf-
ficking is an important part of its function. This importance is
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FIG. 4. Percentage of surface Fas molecules on mononu-
clear cell surfaces in patients with multiple sclerosis, before
and after treatment with IFN-. A significant (*p  0.001)
increase in the percentage of Fas molecules was observed in
the treated MS patients. Fas molecules were quantified by
flow cytometry.
FIG. 5. Percentage of surface Fas molecules on (A) CD4 and
(B) CD8 lymphocytes in patients with multiple sclerosis, both
with and without treatment with IFN-, as well as healthy in-
dividuals. A significant (*p  0.002) increase in the percent-
age of CD4Fas was observed in the treated MS group. Fas
molecules were quantified by flow cytometry.
A
B
emphasized by the fact that the intracellular CTLA4 molecule
is polarized toward those sites facing T cell contact.30,31 As
CTLA4 is known to inhibit the activation of T lymphocytes,
inhibition of autoreactive T cells may be, at least in part, re-
sponsible for the beneficial effects of IFN- treatment.
Despite considerable efforts, the mechanisms by which
CTLA4 molecules exert their suppressive effect on T activa-
tion remain poorly understood. The CTLA4 molecules may
function at least in part by competing with CD28 for CD80/86
ligands, thus serving as an indirect attenuator of costimulatory
signals.32 The crosslinking of CTLA4 molecules may inhibit
IL-2 production and consequent T cell activation,33 and there
is also the possibility of an indirect mode of action of CTLA4,
as its engagement costimulates the secretion of inhibitory cy-
tokines, such as transforming growth factor- (TGF-). A
CTLA4 molecule facilitates TGF--mediated suppression by
intensifying the TGF- signal at the point of suppressor cell-
target cell interaction.34 Moreover, in recent studies, the in-
volvement of the CTLA4 molecule in the induction of
CD4CD25 T cells expressing FOXp3 through TGF- sig-
naling has also been reported.35,36 CTLA4 crosslinking may in-
duce T cell apoptosis, as it has been shown that CTLA4
crosslinking on the surface of prestimulated murine T lympho-
cytes leads to the death of those T lymphocytes.37
There is considerable evidence that apoptosis of the myelin
autoreactive T lymphocytes is deregulated in MS patients. It
has been demonstrated that the activation-induced cell death
triggered by the Fas receptor is impaired in MS patients38–40
and that IFN- treatment reduces the expression of the inhibi-
tors of apoptosis and increases the apoptosis levels of T lym-
phocytes of MS patients.41 In the present study, no direct as-
sociation between the increased expression of CTLA4
molecules and apoptosis was studied, although an increase in
the expression of intracellular CTLA4 molecules was associ-
ated with a simultaneous increase in Fas molecules, both on the
cell surface and in soluble form, after treatment with IFN-.
The results obtained here show significant increase in the ex-
pression of Fas molecules on the surface of leukocytes in a
small group of MS patients after IFN- treatment. Moreover,
a moderate increase in the expression of Fas molecules on the
surface of CD4 T lymphocytes in relation to untreated or nor-
mal control groups reinforces the role of IFN- in the induc-
tion of apoptosis of autoreactive T cells. The expression of Fas
molecules on CD4 Th1 lymphocytes may be linked to the apop-
tosis of these cells, which may be involved in the development
of MS. Thus, the absence or decrease in the expression of the
Fas molecule may be indicative of worsening of the disease.
Fas molecules also occur in a soluble form (sFas), which
lacks a transmembrane region and is present in normal human
sera. As has been shown here, both groups of treated and un-
treated MS patients show an increase in sFas molecules, al-
though treatment significantly reduced the level. Previous find-
ings have demonstrated that an increase in sFas molecules is
associated with disease activity.42 Thus, reduction in these mol-
ecules may be beneficial for MS patients. The results obtained
here may be a reflection of this, but it could also be that in some
way, the presence of sFas may prevent cells from undergoing
Fas-induced apoptosis,43,44 thus playing a role in modulation of
the process.
Taken together, the results presented here provide evidence
of the complexity of the mechanisms that control T cell acti-
vation in MS patients. IFN- treatment reduces the prolifera-
tive response of lymphocytes to myelin antigens as well as in-
ducing the expression of intracellular CTLA4 molecules and
surface Fas molecule on CD4 T lymphocytes. This increase in
surface Fas molecules should be favorable to the induction of
apoptosis; although sFas molecules released during treatment
may result in the survival of some of the T cells. Thus, the ben-
eficial effects of IFN- treatment, that is, reduction of myelin-
specific T cell activation and reduction in clinical signs, may
occur because the mechanisms of apoptosis have prevailed, thus
reducing the inflammatory response despite the presence of
sFas.
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